CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate

--------------------------------------------------------------------------------
ots.CorporateNews transmitted by euro adhoc. The issuer is responsible for
the content of this announcement.
--------------------------------------------------------------------------------

research

Bothell (euro adhoc) - May 28 -- CellCyte Genetics Corporation
(CellCyte) (OTC Bulletin Board: CCYG) has entered into a
collaborative research agreement with Northwestern University's
Feinberg School of Medicine to perform an acute myocardial infarction
(AMI) disease model study in mice using CellCyte's CCG-TH30 product
candidate. The goal of the study is to evaluate the functional
benefit of the CCG-TH30 therapy in a disease model outcome study
representative of the AMI (heart attack) indication. Douglas W.
Losordo, M.D., a leader in cardiovascular cell therapy research and
Director of Feinberg Cardiovascular Research Institute, will serve as
the principal investigator on the study.

"We are extremely pleased to collaborate with Dr. Losordo, as he is one of
the preeminent leaders in cardiovascular regenerative medicine," said Ronald W.
Berninger, Ph.D., CellCyte's Chief Scientific Officer. "This is another
important collaboration for our program, as it allows us to evaluate the
functional outcome benefit of the CCG-TH30 therapy as compared to standard cell
therapies where delivery agents aren't used."

About Douglas W. Losordo, M.D.
Dr. Losordo is a cardiologist at Northwestern Memorial Hospital and is the
Director of Cardiovascular Regenerative Medicine and the Feinberg Cardiovascular
Research Institute, both at Northwestern Memorial Hospital. He is board
certified in Cardiovascular Disease, Internal Medicine, and Interventional
Cardiology. Dr. Losordo is a member of the Northwestern Memorial Faculty
Foundation, and his clinical interests include gene therapy, stem cell
transplant, regenerative medicine and angiogenesis. He has preclinical expertise
in animal models of cardiac disease, as well as preclinical and clinical
expertise in stem cell therapy for cardiac regeneration. In recognition of his
continued and outstanding achievements, Northwestern University's Feinberg
School of Medicine named Dr. Losordo the Eileen M. Foell Professor of Heart
Research in May 2007. He is a fellow of the American College of Cardiology, the
American Heart Association, the American Association for the Advancement of
Science, the American College of Physicians, the American College of Chest
Physicians, and the Society for Cardiac Interventions and Angiography.

About Feinberg Cardiovascular Research Institute at Northwestern University
Originally established in 1988, the Feinberg Cardiovascular Research
Institute is dedicated to pursuing an understanding of the fundamental molecular
and cellular processes underlying cardiovascular disease, the largest
contributor to morbidity and mortality in the United States. The mission of
Feinberg Cardiovascular Research Institute is to improve the quality of human
life through creative basic and translational research in cardiovascular
disease, and to build a legacy of outstanding scholarship, scientific
achievement, and therapeutic discovery. Investigators at Feinberg Cardiovascular
Research Institute are exploring complex problems in modern cardiovascular
research, including basic cellular signaling pathways and their contributions to
disease, the use of stem cells in regenerative medicine, and diagnostic and
imaging technologies critical to patient care.

About CellCyte Genetics
CellCyte Genetics Corporation is a biotechnology company engaged in the
discovery, development and commercialization of stem cell enabling therapeutic
products. CellCyte is developing products designed to allow more efficient
delivery and increased retention of adult stem cells to diseased organs, such as
the heart. The goal of these therapies is to increase the number of stem cells
delivered to a damaged organ, thereby markedly increasing organ healing and
functional restoration. The Company's lead product in development,
CCG-TH30, is designed to send autologous bone marrow-derived (adult) stem cells
to the heart of patients after a heart attack.

For further information see: www.cellcyte.com .

Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.

Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS
DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED,
AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE
FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS,
EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL
INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN
FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES
THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS,
PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS
THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY,
FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE,"
"PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE

FORWARD-LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY
INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE
RESEARCH AND DEVELOPMENT OF CCG-TH30. OTHER RISKS INCLUDE RISKS
ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS
AND COMPANIES, AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS
RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT
THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL
ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING
STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE
COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING
STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER
FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE
COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS, AND
INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN
BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR INTENTIONS
WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE
INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK
FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM
TIME-TO-TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE
COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS ON FORM
10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY
MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS
CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES
NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE.

SOURCE CellCyte Genetics Corporation

-0- 05/28/2008
/Web site: http://www.cellcyte.com /
(CCYG)

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: CellCyte Genetics Corporation
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Investor Relations of CellCyte Genetics Corporation, +1-877-688-5050,
Investorrelations@cellcyte.com

Branche: Biotechnology
ISIN: US15116P1030
WKN: A0MLCV
Börsen: Börse Frankfurt / Open Market
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse München / free trade